Contact us 24/7


Avelox Associated with Increased Risk of Tendonitis and Tendon Rupture

Avelox was approved by the U.S. Food and Drug Administration (FDA) in December of 1999 to treat acute bacterial sinusitis, chronic bronchitis, and moderate pneumonia. The drug was later approved to be effective in treating skin and skin structure infections and complicated intra-abdominal infections.

Avelox is to be administered to only adults of 18 years and older. As of 2008, Avelox is associated with increased risk of tendonitis and tendon rupture.


  • Avelox, along with other fluoroquiniolone drugs, present a higher risk of tendonitis, tendon rupture, and tendinopathy in patients. The U.S. Food and Drug Administration last announced an Avelox boxed label change to educate consumers of this risk.
  • Though tendinitis and tendon rupture has occurred in patients using Avelox of all ages, this effect is most common in patients over the age of 60.
  • The problem of tendinitis and/or tendon rupture while using Avelox has been reported to occur most frequently in the Achilles tendon, located in the back of the lower leg. A tear or rupture of this tendon may require surgery.  Other injuries of this nature associated with Avelox have been reported in the shoulders, hand and bicep.
  • The FDA urges patients to stop taking Avelox immediately and to contact their physician if experiencing rupture, pain or swelling of tendons after intake of the medication. However, tendon injuries have been reported months after completion of the antibiotic. If excess tendon swelling, pain, or rupture happens after completion of Avelox treatment, patients should contact their primary care physician immediately.


According to DrugCite, common adverse side effects associated with Avelox include:

  • Anaphylactic Reaction
  • Uncomfortable breathing
  • Dizziness/lightheadedness
  • Rash
  • Hypersensitivity
  • Nausea
  • Pruritus (Itchiness)
  • Urticaria (Hives)
  • Vomitting
  • Diarrhea


If you’ve been injured, we can help. Contact us